BioSpace News Archive

Drug Development

ZIOPHARM Oncology Announces First Patient Dosed in New Phase I Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors

ZIOPHARM announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment of pediatric brain tumors.

October 16, 2017

·

7 min read

Biotech Beach

Children’s Hospital Los Angeles Release: A Liquid Biopsy For Retinoblastoma Developed By Children’s Hospital Los Angeles And Keck Medicine Of USC

Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed using a biopsy, retinoblastoma tumors cannot be directly biopsied.

October 16, 2017

·

7 min read

BioMidwest

Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies

Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs.

October 16, 2017

·

4 min read

Biotech Bay

Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected For Late Breaking Oral Presentation At The Society For Immunotherapy Of Cancer (SITC) 32nd Annual Meeting

Five Prime Therapeutics today announced that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo® (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor.

October 16, 2017

·

2 min read

Policy

Novo Nordisk: FDA Posts Briefing Materials Prior To Advisory Committee Meeting for Semaglutide

Novo Nordisk announced that the FDA has published the briefing documents ahead of the Advisory Committee meeting to discuss the NDA for approval of semaglutide.

October 16, 2017

·

1 min read

Drug Development

Innate Pharma: IPH4102 - Final Results of the Dose-Escalation Part of the Phase I Study

Innate Pharma announces that final results of the dose-escalation part of the ongoing Phase I study investigating IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas.

October 16, 2017

·

6 min read

Drug Development

Probiodrug Initiates Phase IIb Core Program of PQ912 and Details Further Strategy

Probiodrug has signed a Letter of Agreement with the CRO Julius Clinical in order to continue the excellent collaboration of the SAPHIR study into the next development step.

October 16, 2017

·

6 min read

Intellipharmaceutics Announces Closing of $4M Financing

Intellipharmaceutics announced today the closing of its previously announced registered direct offering consisting of 3,636,364 common shares at a price of US$1.10 per share for gross proceeds of approximately US$4 million.

October 16, 2017

·

11 min read

Business

Analogic Appoints Joseph Whitters to Board of Directors

Mr. Whitters joins the Analogic Board with significant experience in healthcare, finance and strategic transactions.

October 16, 2017

·

4 min read

Deals

Week In Review: Shanghai Pharma Bids In Cardinal China’s $1.5 Billion Auction

Shanghai Pharma and FountainVest Partners, a China PE fund, submitted second-round bids for Cardinal China’s $1.5 billion drug distribution operations.

October 16, 2017

·

1 min read